Latin America’s obesity burden climbed across every age group in the GBD 2023 analysis
Latin America is moving deeper into a high-BMI epidemic that now reaches children, adolescents, and adults with striking consistency. A new Global Burden of Disease 2023 analysis mapped prevalence of overweight and obesity across the region from 1990 to 2023, and the pattern is difficult to ignore: rates rose in nearly every setting, with the steepest acceleration seen in younger people. The regional burden has become large enough that high BMI is no longer a secondary public health concern. It now sits among the dominant drivers of disability and premature death.
The analysis also makes clear that the burden is not evenly distributed. Mexico, Chile, Colombia, and other countries each sit at different points on the same trajectory, but the direction is the same. Urbanisation, physical inactivity, and the replacement of traditional diets with ultra-processed foods are not abstract social trends in this context; they are the background conditions behind the numbers.
Mexico and Chile recorded the highest prevalence at different life stages
The study separated estimates by country and sex across three age bands: children aged 5 to 14 years, adolescents and young adults aged 15 to 24 years, and adults aged 25 years and older. In 2023, Mexico had the highest age-standardised prevalence of overweight and obesity among children, at 28.4%. Among adolescents and young adults, Chile led the region at 51.9%.
Adults showed the greatest absolute burden. Across Latin America, an estimated 274 million people, or 72.1% of adults, were overweight or obese in 2023. Of those, 127 million met criteria for obesity. Chile again stood out, with the highest age-standardised prevalence among adults at 79.9%.
One sentence captures the scale of the shift: the region has normalised excess body weight at a population level.
The pace of change matters as much as the level itself. Colombia posted the fastest percentage increase in adult overweight and obesity from 1990 to 2023, with growth of 68.9%. Across most subregions, adult obesity climbed by more than 0.7 percentage points per year since 2015. That is not a slow drift in exposure; it is a sustained upward slope that raises future demand for diabetes care, cardiovascular management, chronic kidney disease services, and long-term rehabilitation.
Youth obesity is rising fast enough to reshape future disease patterns
The sharpest warning in the analysis comes from the youngest groups. Between 1990 and 2023, obesity prevalence rose by 346.3% among adolescents and young adults. That trajectory matters because cardiometabolic disease does not wait until midlife to begin. Excess adiposity in adolescence increases the likelihood of insulin resistance, hypertension, dyslipidaemia, and vascular injury years before those outcomes are coded in hospital records.
A younger cohort with sustained weight gain changes the future patient mix for health systems. Clinicians will see more early-onset type 2 diabetes, more metabolic syndrome, and more kidney and cardiovascular complications at ages when those conditions once seemed less common. The data suggest that current prevention strategies are not keeping pace with environmental drivers of weight gain.
Children aged 5 to 14 years remain a critical blind spot. The investigators explicitly call for better collection of measured BMI data in this group, which is an important methodological point. Self-reported or incomplete data can blur the true scale of childhood obesity, especially when surveillance systems are uneven across countries. Without stronger child-level measurement, policy makers risk underestimating the base from which adult disease is developing.
High BMI already accounts for millions of lost healthy years
In 2023, high BMI accounted for 15.8 million DALYs in Latin America. Mexico again had the heaviest burden, with an age-standardised DALY rate of 3414.2 per 100,000. The study assessed attributable burden across 26 outcomes, and the leading contributors for both sexes were diabetes mellitus, ischaemic heart disease, and chronic kidney disease.
Those causes form a predictable but still costly chain. Excess adiposity promotes insulin resistance and chronic inflammation, which then accelerate vascular damage, glomerular stress, and atherosclerotic disease. The burden therefore does not sit in isolation within obesity clinics or endocrinology wards. It spreads into cardiology, nephrology, primary care, and emergency services.
The study also makes a useful distinction between age-standardised rates and absolute counts. In Argentina, Chile, Colombia, and Uruguay, age-standardised DALY rates attributable to high BMI did not show a clear increase because the uncertainty intervals included zero, and age-standardised death rates declined. Even so, the absolute number of attributable DALYs rose in all four countries because populations grew older and larger. For health planners, that difference is crucial. A stable rate can still hide a rising caseload.
High BMI is now one of the leading risks for women in much of the region
The interpretation section places high BMI among the three leading risk factors for DALYs among females in most Latin American countries. That is a major shift in regional risk architecture. It means obesity is no longer merely one chronic disease contributor among many; in many settings it has become a central determinant of total female health loss.
This has direct implications for maternal health, diabetes prevention, cardiovascular screening, and chronic disease management across the life course. It also raises the stakes for interventions that begin early, before children move into adolescence and before excess weight becomes established. The data do not support a wait-and-see approach. They point toward prevention that starts in schools, neighborhoods, food systems, and primary care.
The study used spatiotemporal Gaussian process regression to generate estimates and adjusted for self-reported data, while also incorporating 70 new microdata sources and one new report in the GBD 2023 round. Those additions strengthen the regional picture, but they also remind readers that surveillance quality still varies. Countries with the least robust measured data may be the hardest to estimate accurately, which is exactly where improved monitoring is most needed.
Better measurement in children will determine whether policy can keep up
The clearest operational recommendation is the call for measured BMI data in children aged 5 to 14 years. That request is modest in wording and large in consequence. If childhood obesity is underestimated, then prevention budgets, school-based interventions, and clinical screening thresholds will all rest on weaker evidence than they should.
The broader message is more immediate: Latin America is already carrying a substantial and widening burden from high body-mass index, and the youngest cohorts are moving fastest. The region’s future cardiovascular, renal, and metabolic burden is being shaped now, not years from now. The study does not leave much room for complacency, especially in countries where obesity is rising quickly and the health system will have to absorb more diabetes, heart disease, and kidney disease tied to excess weight.